Letrozole as upfront endocrine therapy for postmenopausal women with hormone-sensitive breast cancer: BIG 1-98
Open Access
- 3 October 2007
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 105 (S1) , 55-66
- https://doi.org/10.1007/s10549-007-9700-y
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trialThe Lancet, 2007
- Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98Journal of Clinical Oncology, 2007
- Progress and new standards of care in the management of HER-2 positive breast cancerEuropean Journal Of Cancer, 2007
- A Comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast CancerNew England Journal of Medicine, 2005
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- Distinct breast cancer incidence and prognostic patterns in the NCI?s SEER program: suggesting a possible link between etiology and outcomeBreast Cancer Research and Treatment, 2005
- A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast CancerNew England Journal of Medicine, 2004
- A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast CancerNew England Journal of Medicine, 2003
- Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trialThe Lancet, 2002
- Estrogen-Like Action of Tamoxifen on Vaginal Epithelium in Breast Cancer PatientsOncology, 1981